Clinical trial

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-01-01

PhasePHASE3

Study timeline

Study start (unknown)2009-01-01Date precision: month

Registry last updated2014-06-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

single-use autoinjector with a prefilled liquid Avonex syringeDEVICE

Avonex prefilled syringe via manual IM injectionDEVICE

BG9418 (interferon beta-1a)DRUG

Sponsors & collaborators

Biogenlead sponsor

Mapped research locations

BostonMassachusetts, United States1 DallasTexas, United States1 AtlantaGeorgia, United States1 PhoenixArizona, United States1 Salt Lake CityUtah, United States1 CharlotteNorth Carolina, United States1 RichmondVirginia, United States1 BuffaloNew York, United States1 AkronOhio, United States1 Fort WayneIndiana, United States1 Farmington HillsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00828204 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.